Shenzhen YaXinXuan Trading Co., LTD – Trademark Portfolio

Entity Type: 16

Shenzhen YaXinXuan Trading Co., LTD holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include COFUNEE. The owner is based in Shenzhen, Guangdong.

302, Building 6, Customs Living Area, No. 1026 Buji Road,

Greenview Community, Dongxiao Street, Luohu District,

Shenzhen, Guangdong 518000 , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

COFUNEE
COFUNEE
Registered 2025

Trademark Classifications

Shenzhen YaXinXuan Trading Co., LTD's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Shenzhen YaXinXuan Trading Co., LTD have?

Shenzhen YaXinXuan Trading Co., LTD has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does Shenzhen YaXinXuan Trading Co., LTD file in?

Shenzhen YaXinXuan Trading Co., LTD files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Shenzhen YaXinXuan Trading Co., LTD's most well-known trademarks?

Shenzhen YaXinXuan Trading Co., LTD's registered trademark portfolio includes well-known marks such as COFUNEE. These are among 1 currently registered trademark in the portfolio.

What is Shenzhen YaXinXuan Trading Co., LTD's trademark registration success rate?

Shenzhen YaXinXuan Trading Co., LTD has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.